Syndax Pharmaceuticals SNDX Business Segments — Personnel Cost And Other Expenses

Similar metrics at other companies

DNLITherapeutics Segment — Personnel related research and development expenses

$40.11M-0.4%

VCYTBiopharmaceutical and other revenue — Other cost

$8K-99.2%

DNLITherapeutics Segment — Personnel related selling, general and administrative expenses

$22.92M+13.9%

VCYTBiopharmaceutical and other revenue — Compensation expense

$0-100%

VCYTBiopharmaceutical and other revenue — Cost of Revenue

$8K-99.7%

ITOther — Personnel expenses

$2.21M-78.7%

FAQ

What is Syndax Pharmaceuticals's business segments — personnel cost and other expenses?

Syndax Pharmaceuticals (SNDX) reported business segments — personnel cost and other expenses of $19.3M in Q1 2026.

How has Syndax Pharmaceuticals's business segments — personnel cost and other expenses changed year-over-year?

Syndax Pharmaceuticals's business segments — personnel cost and other expenses increased by 16.7% year-over-year, from $16.53M to $19.3M.

What is the long-term trend for Syndax Pharmaceuticals's business segments — personnel cost and other expenses?

Over 3 years (2022 to 2025), Syndax Pharmaceuticals's business segments — personnel cost and other expenses has grown at a 45.0% compound annual growth rate (CAGR), from $25.52M to $77.89M.

What does business segments — personnel cost and other expenses mean?

This metric tracks the compensation, benefits, and related operational costs for staff dedicated specifically to the cancer therapeutics segment. It reflects the human capital investment required to advance clinical programs and manage commercial operations. Rising costs in this category often correlate with the expansion of clinical trial teams or commercial sales forces.